The European Commission is advancing plans for a comprehensive EU Biotech Act, aiming to bolster biotechnology and biomanufacturing across the Union. This initiative seeks to streamline regulatory frameworks, enhance investment, and foster innovation in sectors ranging from healthcare to sustainable materials. A public consultation has been launched to gather insights from stakeholders, ensuring that the Act addresses current challenges and harnesses the full potential of biotech for Europe’s competitiveness and sustainability goals.
The Global Organization for PHA (GO!PHA) took this opportunity to identify the major regulatory challenges for biopolymers like PHAs made via novel biotechnologies in the current EU legislative framework, highlighting a consistent theme: innovation in bio-based and biodegradable materials is hindered by outdated or misaligned legislations.
📢 Call to action: Align legislation to reflect scientific progress and material innovation contributing to EU’s broad goals—circular bio manufactured materials must be supported with harmonized standards, guidelines, and assessments, not be hindered by one-size-fits-all policies.
